# The Prognostic Indicators of Progression From Solitary Plasmacytoma to Multiple Myeloma: A Narrative Review

## TL;DR

This paper reviews factors that predict the progression of solitary plasmacytoma to multiple myeloma, emphasizing the need for better risk assessment tools.

## Contribution

The paper provides a synthesis of prognostic indicators for progression from solitary plasmacytoma to multiple myeloma.

## Key findings

- High-risk cytogenetic abnormalities are strongly associated with faster progression to multiple myeloma.
- Tumor size, age, and persistent M-protein levels after treatment are significant prognostic factors.
- Standardized risk stratification systems are needed to guide treatment and surveillance decisions.

## Abstract

Solitary plasmacytomas (SPs), encompassing both solitary bone plasmacytoma (SBP) and extramedullary plasmacytoma (EMP), are rare plasma cell neoplasms that carry a risk of progression to multiple myeloma (MM). This review synthesizes current literature on the prognostic indicators predictive of such progression. High-risk cytogenetic abnormalities have been consistently linked to faster transition to MM. Other factors, such as tumor size, age, and persistent M-protein levels after treatment, are also prognostic factors. While radiotherapy remains the cornerstone of treatment, its curative potential is influenced by these indicators. Time to progression to MM is highly variable. This review highlights the need for standardized risk stratification systems to guide surveillance and treatment decisions in patients with SP.